Trial Profile
Pioglitazone for the Treatment of Major Depressive Disorder Comorbid With Metabolic Syndrome.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2016
Price :
$35
*
At a glance
- Drugs Pioglitazone (Primary)
- Indications Major depressive disorder; Metabolic syndrome
- Focus Therapeutic Use
- 13 Dec 2011 Actual end date (1 Nov 2011) added as reported by ClinicalTrials.gov.
- 13 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Aug 2011 Planned end date changed from 1 Jan 2011 to 1 Nov 2011 as reported by ClinicalTrials.gov.